# Licofelone

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/licofelone
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** ML3000, dual COX-LOX inhibitor, diphenylpyrrole anti-inflammatory, synthetic LOX-COX inhibitor

## Overview

Licofelone is a synthetic [anti-inflammatory](/ingredients/condition/inflammation) compound that acts as a dual inhibitor of cyclooxygenase (COX-1/COX-2) and 5-lipoxygenase (5-LOX) enzymes, simultaneously suppressing both prostanoid and leukotriene biosynthesis. This dual-pathway blockade distinguishes it from conventional NSAIDs and has been primarily investigated as a disease-modifying candidate for osteoarthritis.

## Health Benefits

• Investigated for osteoarthritis treatment as a dual COX/LOX inhibitor, but lacks large-scale clinical trial data.
• Reduces prostanoid biosynthesis, potentially lowering inflammation markers.
• Inhibits leukotriene biosynthesis, targeting [inflammatory pathway](/ingredients/condition/inflammation)s.
• Aims to provide anti-inflammatory effects without traditional NSAID side effects, based on its mechanism.
• Potentially minimizes gastrointestinal issues common with NSAIDs, inferred from its dual inhibition mechanism.

## Mechanism of Action

Licofelone competitively inhibits both cyclooxygenase isoforms (COX-1 and COX-2) and 5-lipoxygenase (5-LOX), blocking the conversion of arachidonic acid into pro-inflammatory [prostaglandin](/ingredients/condition/inflammation)s, thromboxanes, and leukotrienes (particularly LTB4 and LTC4). By suppressing 5-LOX-activating protein (FLAP) interactions alongside COX enzymes, it prevents the arachidonic acid cascade from shunting exclusively toward the leukotriene pathway — a compensatory problem seen with selective COX-2 inhibitors like celecoxib. This dual inhibition results in a broader reduction of eicosanoid-mediated inflammation without the [cardiovascular risk](/ingredients/condition/heart-health)s associated with leukotriene overproduction.

## Clinical Summary

The most notable clinical evidence comes from a randomized controlled trial published in Arthritis & Rheumatism (2004) involving approximately 355 knee osteoarthritis patients, where licofelone (200 mg twice daily for 24 months) significantly reduced cartilage volume loss compared to naproxen as measured by MRI. A follow-up study confirmed reductions in biomarkers of cartilage degradation, including urinary CTX-II (C-terminal telopeptide of type II collagen) and serum CS-846, suggesting disease-modifying rather than purely symptomatic effects. Pain scores and WOMAC indices improved comparably to naproxen, but sample sizes across trials remain small and no Phase III regulatory trials have been completed. Overall, evidence is promising but insufficient to support licofelone as a clinically approved therapy, limiting conclusions about long-term efficacy and safety.

## Nutritional Profile

Licofelone is a synthetic pharmaceutical compound (molecular formula C26H25NO2S, MW ~419.55 g/mol), not a dietary ingredient, and therefore carries no macronutrients, micronutrients, vitamins, minerals, or fiber content. Its bioactive profile is defined entirely by its pharmacological activity: it is a dual inhibitor of cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) enzymes, functioning at micromolar concentrations (IC50 values reported in the range of 0.1–1 µM for COX and 5-LOX inhibition in preclinical studies). Investigational oral dosing in clinical trials for osteoarthritis has typically ranged from 200–400 mg/day. It reduces [prostaglandin](/ingredients/condition/inflammation) E2 (PGE2), thromboxane B2, and leukotriene B4 (LTB4) biosynthesis simultaneously. Bioavailability data from human studies is limited, but animal models suggest reasonable oral absorption with hepatic [metabolism](/ingredients/condition/weight-management). No caloric, glycemic, or micronutrient contributions are applicable.

## Dosage & Preparation

No clinically studied dosage ranges or forms are specified, as licofelone remains an investigational compound without approved therapeutic use. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

In clinical trials at doses of 200–400 mg/day, licofelone demonstrated a gastrointestinal tolerability profile superior to naproxen, with fewer endoscopic ulcer findings attributed to partial COX-1 sparing relative to traditional NSAIDs. However, because licofelone retains COX-1 inhibitory activity, risks of gastrointestinal bleeding and renal [prostaglandin](/ingredients/condition/inflammation) suppression cannot be excluded, particularly in patients with pre-existing renal impairment or peptic ulcer disease. Concurrent use with anticoagulants (warfarin, heparin), other NSAIDs, or antiplatelet agents may potentiate bleeding risk due to combined prostanoid suppression. Safety data during pregnancy and lactation are absent from published literature, and its use in these populations should be avoided until established.

## Scientific Research

Licofelone was primarily studied in phase II and III clinical trials for osteoarthritis, but detailed data such as PMIDs, study designs, or outcomes are not available. Development by Merckle GmbH appears discontinued.

## Historical & Cultural Context

Licofelone has no traditional or historical use as it is a fully synthetic compound. It does not have any origins in historical medicinal systems.

## Synergistic Combinations

Licofelone pairs mechanistically with omega-3 fatty acids (EPA/DHA at 2–4 g/day), which serve as competitive substrates for both COX and 5-LOX enzymes, shifting eicosanoid production toward less pro-inflammatory resolvins and protectins — complementing Licofelone's enzyme inhibition with substrate-level redirection. Boswellic acids (specifically AKBA from Boswellia serrata, ~100–200 mg/day standardized extract) add a third [anti-inflammatory](/ingredients/condition/inflammation) axis by inhibiting 5-LOX independently through a non-competitive mechanism and also suppressing NF-κB signaling, creating additive pathway coverage beyond Licofelone's direct enzyme binding. Curcumin (500–1000 mg/day with piperine for enhanced bioavailability) further complements this stack by downregulating NF-κB transcription and COX-2 gene expression upstream, while also offering chondroprotective effects via MMP inhibition relevant to Licofelone's osteoarthritis indication — together these three ingredients address enzymatic, transcriptional, and substrate-level inflammatory regulation across overlapping but distinct molecular targets.

## Frequently Asked Questions

### What is licofelone used for?

Licofelone has been primarily investigated for the treatment of osteoarthritis, where it functions both as a pain-relieving and potentially cartilage-protective agent. Unlike standard NSAIDs, its dual COX/5-LOX inhibition may slow structural joint deterioration, as evidenced by reduced MRI-measured cartilage volume loss in a 24-month randomized trial. It is not currently approved by the FDA or EMA for any indication.

### How does licofelone differ from NSAIDs like ibuprofen or celecoxib?

Standard NSAIDs inhibit only cyclooxygenase enzymes (COX-1 and/or COX-2), which can cause arachidonic acid to be shunted toward the 5-lipoxygenase pathway, increasing leukotriene production and potentially raising cardiovascular risk (as seen with selective COX-2 inhibitors). Licofelone blocks both COX isoforms and 5-LOX simultaneously, preventing this compensatory leukotriene surge and achieving broader eicosanoid suppression. This mechanism theoretically reduces both gastrointestinal and cardiovascular adverse effects compared to celecoxib or naproxen.

### What is the typical dosage of licofelone studied in clinical trials?

The most studied dosage in clinical trials is 200 mg taken twice daily (400 mg/day total), administered orally over periods ranging from 4 weeks to 24 months. The 24-month knee osteoarthritis trial used this dose and compared it directly against naproxen 500 mg twice daily. Optimal dosing for other inflammatory conditions has not been established, as licofelone remains an investigational compound.

### Does licofelone actually protect cartilage in osteoarthritis?

Clinical evidence suggests licofelone may offer cartilage-protective effects beyond symptom relief. In a randomized trial of approximately 355 patients, MRI analysis after 24 months showed significantly less cartilage volume loss in the licofelone group compared to naproxen-treated patients. Biomarkers of cartilage breakdown, specifically urinary CTX-II and serum CS-846 aggrecan epitope, were also measurably reduced, supporting a disease-modifying hypothesis, though larger confirmatory trials are still needed.

### Is licofelone safe to take with blood thinners or other anti-inflammatory drugs?

Licofelone inhibits prostanoid biosynthesis including thromboxane A2, which plays a role in platelet aggregation, meaning concurrent use with anticoagulants like warfarin or antiplatelet drugs like aspirin and clopidogrel may significantly increase bleeding risk. Combining it with other NSAIDs would likely compound gastrointestinal and renal risks without additive anti-inflammatory benefit. No formal drug-interaction pharmacokinetic studies have been published, so caution and medical supervision are strongly advised before combining licofelone with any of these medications.

### What is the current regulatory status of licofelone in different countries?

Licofelone is not approved by the FDA in the United States and remains an investigational agent, though it has been studied in clinical trials in Europe and other regions. Its regulatory pathway has been limited compared to established osteoarthritis treatments, partly due to the need for more extensive safety and efficacy data from large-scale studies. Availability and approval status vary significantly by country, with some markets having more advanced clinical development than others.

### How does licofelone's dual COX/LOX inhibition mechanism affect side effect profile compared to standard NSAIDs?

By targeting both cyclooxygenase (COX) and lipoxygenase (LOX) pathways, licofelone theoretically reduces inflammation through multiple mechanisms while potentially minimizing gastrointestinal side effects associated with traditional NSAIDs that primarily inhibit COX enzymes. The LOX inhibition may lower leukotriene production, which contributes to inflammatory responses without the same gastric irritation risk as COX-only inhibitors. However, clinical evidence confirming a significantly improved safety profile in humans remains limited.

### What populations or osteoarthritis stages might benefit most from licofelone based on available research?

Early to moderate osteoarthritis patients may be the target population for licofelone, as some studies suggest it may slow cartilage degradation when administered in earlier disease stages. Patients who experience gastrointestinal intolerance to traditional NSAIDs or COX-2 selective inhibitors could theoretically be candidates, though this benefit has not been definitively proven in large clinical trials. Additional research is needed to identify which patient subgroups derive the greatest benefit relative to established osteoarthritis treatments.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*